Kodiak Sciences Inc. is a biopharmaceutical company based in Palo Alto, California, that focuses on the discovery, development, and commercialization of novel therapies for the treatment of retinal diseases. Founded in 2009, Kodiak Sciences is particularly known for its innovative approaches to address age-related macular degeneration (AMD) and other retinal disorders. The company leverages its proprietary technology platform, known as the Antibody Biopolymer Conjugate (ABC) Platform, to create optimized therapeutic candidates.
The flagship product in Kodiak Sciences' pipeline is KSI-301, a potential breakthrough treatment for retinal vascular diseases. KSI-301 is designed as an anti-VEGF (vascular endothelial growth factor) biopolymer conjugate, aiming to provide an extended duration of action and increased potency compared to existing treatments. The company is conducting clinical trials to evaluate the safety and efficacy of KSI-301 across various retinal diseases, including AMD and diabetic macular edema.
Kodiak Sciences has attracted attention for its unique approach to retinal disease treatment, with a focus on reducing treatment burden for patients by extending the durability of therapeutic effects. The company's commitment to innovation is complemented by its efforts to advance the understanding of retinal biology and develop targeted therapies that address the underlying mechanisms of these diseases.